Yin Yin Sheng

Ms. Yin Yin Sheng

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ASAbdul Shakerdi
Abdul Shakerdi
EFEmma Finnegan
Emma Finnegan
YSYin Yin Sheng
Yin Yin Sheng
GPGraham Pidgeon
Graham Pidgeon
Background: Nasopharyngeal carcinoma (NPC) is an epithelial malignancy arising from the nasopharyngeal mucosa. Despite treatment advances such as the use of intensity-modulated radiotherapy and immune checkpoint inhibitors, resistance remains a significant clinical challenge. Many tumours are also diagnosed at an advanced stage associated with poor prognosis. Objective: This review aims to explore the biological roles of autophagy in NPC, primarily highlighting its involvement in disease pathogenesis and treatment resistance. Methods: We performed a review of the recent literature examining the role of autophagy-related pathways in NPC pathogenesis, biomarker discovery, and therapeutic targeting. Results: Autophagy plays a dual role in NPC as it contributes to both tumour suppression and progression. It is involved in tumour initiation, metastasis, immune modulation, and treatment resistance. Autophagy-related genes such as SQSTM1, Beclin-1, and AURKA may serve as prognostic and therapeutic biomarkers. Various strategies are being investigated for their role to modulate autophagy using pharmacologic inhibitors, RNA interventions, and natural compounds. Conclusions: Further research into autophagy’s context-dependent roles in NPC may inform the development of personalised therapies and allow progress in translational and precision oncology.

14 October 2025 in Cells
Verified
Journal Article
Open access
PDF file
ASAbdul Shakerdi
Abdul Shakerdi
EFEmma Finnegan
Emma Finnegan
YSYin Yin Sheng
Yin Yin Sheng
KVKarlo Vidovic
Karlo Vidovic
JLJessica M Logan
Jessica M Logan
PTPrerna Tewari
Prerna Tewari
Epithelial-mesenchymal transition (EMT) and inflammasome signalling are intercon-nected processes which underpin tumour progression, metastasis, and therapeutic re-sistance. Inflammasomes such as NLRP3 encourage pro-inflammatory states (IL-1β, IL-18, NF-κB) and the activation of signalling pathways like TGF-β that promote mes-enchymal traits crucial for EMT. EMT transcriptional programmes can then in turn modulate the inflammasome via NF-κB/TGF-β signalling, creating self-perpetuating mechanisms of cellular plasticity and dysregulated therapeutic response. We have re-viewed the mechanistic evidence for EMT–inflammasome crosstalk in cancer and discussed the potential therapeutic implications. The function of the EMT-inflammasome axis is clearly context-dependent, with the cancer type, stage, and the complexity of the tumour microenvironment heavily contributing. The crosstalk between EMT and the inflammasome is an overlooked mechanism of tumour evolution, and targeting inflammasomes like NLRP3, or their downstream signalling pathways, offers a promising therapeutic avenue, with the objective of inhibiting metastasis and overcoming drug resistance.

11 September 2025 in Academia Oncology
Verified
Journal Article
Open access
PDF file
YSYin Yin Sheng
Yin Yin Sheng
ASAbdul Shakerdi
Abdul Shakerdi
GPGraham Pidgeon
Graham Pidgeon
Autophagy is an evolutionarily conserved catabolic process that enables cells to degrade and recycle long-lived proteins and damaged organelles, playing an important role in cellular homeostasis and survival under stress. In lung cancer, autophagy has emerged as a key modulator of tumour cell survival and is a significant factor influencing chemotherapy efficacy. However, the contribution of autophagy to chemoresistance remains complex and incompletely understood. Recent studies identify microRNA (miRNAs), a class of small non-coding RNAs, as critical regulators of autophagy, capable of modulating autophagy-related genes and signalling pathways. Through this regulatory capacity, miRNAs can alter autophagic activity in lung cancer cells, thereby influencing both chemosensitivity and the development of chemoresistance. This review summarises current advances in the understanding of the miRNA-mediated regulation of autophagy in the context of lung cancer, with particular emphasis on its impact on chemotherapy response. Mechanistic insights into how miRNAs govern specific stages of the autophagic process are examined, and the potential for therapeutic intervention targeting the miRNA–autophagy axis to mitigate chemoresistance in lung cancer is discussed.

12 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAbdul Shakerdi
Abdul Shakerdi
EFEmma Finnegan
Emma Finnegan
YSYin Yin Sheng
Yin Yin Sheng
KVKarlo Vidovic
Karlo Vidovic
JLJessica M Logan
Jessica M Logan
PTPrerna Tewari
Prerna Tewari
Epithelial-mesenchymal transition (EMT) and inflammasome signaling are interconnected processes which underpin tumour progression, metastasis, and therapeutic resistance. Inflammasomes such as NLRP3 encourage pro-inflammatory states (IL-1β, IL-18, NF-κB) and the activation of signalling pathways like TGF-β that promote mesenchymal traits crucial for EMT. EMT transcriptional programs can then in turn modulate the inflammasome via NF-κB/TGF-β signaling, creating self-perpetuating mechanisms of cellular plasticity and dysregulated therapeutic response. We have reviewed the mechanistic evidence for EMT–inflammasome crosstalk in cancer and discussed the potential therapeutic implications. The function of the ENT-inflammasome axis is clearly context-dependent, with the cancer type, stage, and the complexity of the tumour microenvironment heavily contributing. The between EMT and the inflammasome is an overlooked mechanism of tumour evolution and targeting inflammasomes like NLRP3, or their downstream signalling pathways offer a promising therapeutic avenue, with the therapeutic objective of reducing metastasis and overcoming drug resistance.

17 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAbdul Shakerdi
Abdul Shakerdi
EFEmma Finnegan
Emma Finnegan
YSYin Yin Sheng
Yin Yin Sheng
GPGraham Pidgeon
Graham Pidgeon
Background: Nasopharyngeal carcinoma (NPC) is an epithelial malignancy arising from the nasopharyngeal mucosa. Despite treatment advances such as the use of intensity-modulated radiotherapy and immune checkpoint inhibitors, resistance remains a significant clinical challenge. Many tumours are also diagnosed at an advanced stage associated with poor prognosis. Objective: This review aims to explore the biological roles of autophagy in NPC, primarily highlighting its involvement in disease pathogenesis and treatment resistance. Methods: We performed a review of recent literature examining the role of autophagy-related pathways in NPC pathogenesis, biomarker discovery, and therapeutic targeting. Results: Autophagy plays a dual role in NPC as it contributes to both tumour suppression and progression. It is involved in tumour initiation, metastasis, immune modulation, and treatment resistance. Autophagy-related genes such as SQSTM1, Beclin-1, and AURKA may serve as prognostic and therapeutic biomarkers. Various strategies are being investigated for their role to modulate autophagy using pharmacologic inhibitors, RNA interventions, and natural compounds. Conclusions: Further research into autophagy’s context-dependent roles in NPC may inform the development of personalised therapies and allow progress in translational and precision oncology.